Usted buscó: through week (Inglés - Islandés)

through week 54
niður, út 54. viku.

through week 24 0.40d
eftir 24 vikur 0,40d 0,0016 na

through week 24 0.40d 0.0016 na
eftir 24 vikur 0,40d 0,0016

< 50 copies/ml) through week 48.
< 50 eintök/ml) út viku 48.

the improvement was sustained through week 28.
Árangurinn hélst framyfir viku 28.

number of pulmonary exacerbations through week 24
fjöldi versnana á lungnastarfsemi út 24. viku

median time to loss of response through week 54
einstaklingum skipt af handahófi

dosing continued for all patients through week 46.
skömmtun var haldið áfram hjá öllum sjúklingunum út viku 46.

differences for both endpoints were maintained through week 48.
muninum var viðhaldið fyrir báða endapunkta út viku 48.

improvements in facit scores were maintained through week 52.
breyting til batnaðar með tilliti til facit stiga hélst út viku 52.

change in platelet count through week 26 (109/l)
breyting á blóðflagnafjölda eftir 26 vikur (109/l)

efficacy data were collected and analyzed through week 8 for both studies.
verkunarniðurstöðum var safnað saman og greining var gerð út viku 8 í báðum rannsóknunum.

placebo-controlled efficacy data were collected and analysed through week 16.
lagt var mat á niðurstöður samanburðarrannsókna með lyfleysu eftir viku 16.

maintenance of response (patients in clinical response through week 54)e
viðhald svörunar (sjúklingar með klíníska svörun út

in general, pasi responses were achieved by week 16 and were maintained through week 32.
almennt hafði pasi svörun náðst í viku 16 og hélst út viku 32.

antibodies to infliximab were detected in 4 (7.7%) patients through week 54.
mótefni gegn infliximabi greindust hjá 4 sjúklingum (7,7%) í 54. viku.

this effect was observed at week 1 of treatment and maintained in studies extended through week 104.
Þessi áhrif komu fram á .1 viku meðferðar og voru viðvarandi í framhaldsrannsóknum út 104. viku.

a key secondary endpoint was the continuous abstinence (ca) rate for week 13 through week 52.
annar lykilendapunktur var hlutfall samfellds reykleysis (ca) frá viku 13 til viku 52.

changes in lipids and lipoproteins through week 26 and week 78 of lomitapide treatment are presented in table 5.
breytingar á gildum lípíða og fituprótína út viku 26 og viku 78 af meðferð með lomitapíði eru sýndar í tafla 5.

the dose should be increased to 28 mcg/day starting at week 2 through week 4 of the first cycle.
auka skal skammtinn í 28 míkróg/sólarhring frá viku 2 og út viku 4 í fyrstu lotunni.